Mirae Asset Global Investments Co. Ltd. Purchases 868 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Mirae Asset Global Investments Co. Ltd. increased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 5.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 16,713 shares of the specialty pharmaceutical company’s stock after acquiring an additional 868 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Collegium Pharmaceutical were worth $514,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. China Universal Asset Management Co. Ltd. grew its position in shares of Collegium Pharmaceutical by 320.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock valued at $116,000 after purchasing an additional 2,877 shares in the last quarter. Versor Investments LP bought a new stake in Collegium Pharmaceutical during the third quarter valued at $207,000. Ritholtz Wealth Management purchased a new position in Collegium Pharmaceutical during the fourth quarter worth about $286,000. SG Americas Securities LLC bought a new position in Collegium Pharmaceutical in the 3rd quarter worth about $221,000. Finally, O Shaughnessy Asset Management LLC raised its holdings in shares of Collegium Pharmaceutical by 14.3% in the 3rd quarter. O Shaughnessy Asset Management LLC now owns 11,509 shares of the specialty pharmaceutical company’s stock valued at $257,000 after acquiring an additional 1,440 shares in the last quarter.

Collegium Pharmaceutical Trading Up 1.0 %

Shares of COLL opened at $35.84 on Friday. Collegium Pharmaceutical, Inc. has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of 30.37 and a beta of 1.03. The firm has a 50 day moving average price of $37.06 and a 200-day moving average price of $31.18. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a net margin of 8.50% and a return on equity of 107.39%. The company had revenue of $149.75 million for the quarter, compared to analysts’ expectations of $147.66 million. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Truist Financial boosted their price objective on Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $40.00 price target on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Piper Sandler restated an “overweight” rating and set a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research report on Friday, February 23rd. StockNews.com upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Finally, Jefferies Financial Group restated a “hold” rating and set a $37.00 price target (up previously from $30.00) on shares of Collegium Pharmaceutical in a research report on Thursday, January 4th. Two equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.